Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
![Business Wire](../../../Content/images/providers/BW.png)
Adicet Bio, Inc. (ACET)
Last adicet bio, inc. earnings: 5/3 05:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aceto.com/ir/index.html
Company Research
Source: Business Wire
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis.“The FDA’s decision to grant ADI-001 Fast Track Designation for lupus nephritis underscores the urgent need for new therapies for this chronic disease,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “We plan to initiate our Phase 1 clinical study in lupus nephritis later this month. With clinical data for ADI-001 in non-Hodgkin’s lymphoma demonstrating CD19+ B-cell depletion that mirrors data by autologous alpha-beta CAR T in academic clinical studies in several autoimmune diseases, we believe we are well positioned to expand our autoimmune progra
Show less
Read more
Impact Snapshot
Event Time:
ACET
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACET alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACET alerts
High impacting Adicet Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ACET
News
- Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma [Yahoo! Finance]Yahoo! Finance
- Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell CarcinomaBusiness Wire
- We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- Adicet Bio, Inc. (NASDAQ: ACET) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis [Yahoo! Finance]Yahoo! Finance
ACET
Earnings
- 5/14/24 - In-Line
ACET
Sec Filings
- 6/24/24 - Form 8-K
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- ACET's page on the SEC website